Vanderbilt University

Qiagen Sciences, LLC

Charles W Stratton

William M Mitchell

Subramaniam Sriram

Jian Han

Yi-Wei Tang

Disclosed is an isolated strain of a previously unknown. Also disclosed are the sequences of thetuf gene and 16s rRNA and methods for distinguishingfrom other staphylococcal species.

[object Object]

The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery thatis present in patients with multiple sclerosis, and that anti-chlamydial agents improve or sustain neurological function in these patients.

Methods and reagents for the treatment of multiple sclerosis

The present invention provides a unique approach for the diagnosis and management of infections byspecies, particularly. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.

Diagnosis and management of infection caused by chlamydia

The present invention provides a unique approach for the diagnosis and management of infections by Chlamydia species, particularly. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.

Diagnosis and management of infection caused by Chlamydia

The present invention provides a unique approach for the diagnosis and management of infections by Chlamydia species, particularly . The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.

The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that Chlamydia is present in patients with multiple sclerosis, and that anti-chlamydial agents improve or sustain neurological function in these patients.

Methods and treatment of multiple sclerosis

Methods for clearing Chlamydia from biological materials, e.g., cells and animals, infected therewith are described. Methods for maintaining Chlamydia-free cells and animals are also described.

Chlamydia-free cell lines and animals

Identification of linear amino acid antigenic sequences for the production of both polyclonal and monoclonal antibodies to defined antigenic domains is described. Also described are antigenic peptides identified by the described methods and antibodies thereto.

Identification of antigenic peptide sequences

Methods for determining the susceptibility of intracellular pathogens, particularly Chlamydia, to single or combination of test agents are described. The methods can be used for in vitro or in vivo evaluation of agents that can be used as therapeutic agents in the treatment/eradication of pathogen infection in general or to target a specific infected organ. Assays which utilize nucleic amplification techniques (e.g., PCR) to determine effectiveness of the agent(s) evaluated are also described.

Growing community of inventors

Nashville, TN, United States of America

Charles W Stratton